Biocon sees GLP-1 weight-loss therapy as a future growth driver

Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 India launch. CEO Shreehas Tambe said both portfolios are complementary. Biocon aims to leverage its insulin experience for GLP-1 success, following US FDA approval for insulin aspart and India approval for liraglutide. External risks remain a key concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dw4pEIK
via IFTTT

Read More

Medical device firms sound the alarm over new steel standards

Earlier, foreign suppliers only needed BIS certification for finished steel products. Under the new rule, materials like hot rolled steel, ingots manufactured by other countries for Indian buyers will have to get BIS certification. The manufacturers have written to the ministry of steel seeking exemption for the import of stainless steel capillary without BIS certification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FurWfSZ
via IFTTT

Read More

Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months

The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro’s revenue could cross Rs 500 crore by March, experts estimate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xLPVHcg
via IFTTT

Read More

Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July

Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, saw sales more than double to 5,000 units, while Mounjaro sales also doubled to 157,000 units. Mounjaro's sales have soared 15 times since its March launch in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AhPSKaq
via IFTTT

Read More

Executive order by US administration excludes Pharma sector from immediate tariff imposition: Indian Pharmaceutical Alliance

The Indian pharmaceutical sector has been excluded from immediate US tariff hikes due to the importance of generic medicines for affordable healthcare in the United States. This follows President Trump's imposition of a 25% tariff on India over Russian oil purchases, raising the total tariff to 50%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bkQCuVn
via IFTTT

Read More

Indian pharma on alert as US mulls higher drug tariffs

Indian drug makers are assessing the potential consequences of additional tariffs imposed by the US in response to India's oil purchases from Russia. While previous tariffs spared pharmaceuticals, uncertainty prevails due to frequent policy changes. Companies are exploring mitigation strategies like price adjustments and technology transfer to the US, anticipating manageable impacts on medicine access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JTxi1wE
via IFTTT

Read More

More heart attacks in diabetes? Here’s what you should know

Type 2 diabetes elevates the risk of heart issues, but advancements offer hope. New treatments not only manage blood sugar but also promote weight loss, lower blood pressure, and improve cholesterol, reducing heart-related hospitalizations. Addressing obesity is crucial, and consulting a doctor about comprehensive diabetes and heart health management is recommended.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GwPz60k
via IFTTT

Read More